Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/41665
Registro completo de metadados
Campo DCValorIdioma
dc.creatorZhu, Zhen-
dc.creatorLu, Zhaohui-
dc.creatorXu, Tianmin-
dc.creatorChen, Cong-
dc.creatorYang, Gang-
dc.creatorZha, Tao-
dc.creatorLu, Jianchun-
dc.creatorXue, Yuan-
dc.date.accessioned2020-07-02T14:06:30Z-
dc.date.available2020-07-02T14:06:30Z-
dc.date.issued2020-07-
dc.identifier.citationZHU, Z. et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. Journal of Infection, [S.l.], v. 81, n. 1, p. e21-e23, July 2020.pt_BR
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0163445320301882pt_BR
dc.identifier.urihttp://repositorio.ufla.br/jspui/handle/1/41665-
dc.description.abstractLopinavir/ritonavir and arbidol have been previously used to treat acute respiratory syndrome- coronavirus 2 (SARS-CoV-2) replication in clinical practice; nevertheless, their effectiveness remains controversial. In this study, we evaluated the antiviral effects and safety of lopinavir/ritonavir and arbidol in patients with the 2019-nCoV disease (COVID-19). Fifty patients with laboratory-confirmed COVID-19 were divided into two groups: including lopinavir/ritonavir group (34 cases) and arbidol group (16 cases). Lopinavir/ritonavir group received 400 mg/100mg of Lopinavir/ritonavir, twice a day for a week, while the arbidol group was given 0.2 g arbidol, three times a day. Data from these patients were retrospectively analyzed. The cycle threshold values of open reading frame 1ab and nucleocapsid genes by RT-PCR assay were monitored during antiviral therapy. None of the patients developed severe pneumonia or ARDS. There was no difference in fever duration between the two groups (P=0.61). On day 14 after the admission, no viral load was detected in arbidol group, but the viral load was found in 15(44.1%) patients treated with lopinavir/ritonavir. Patients in the arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group (P<0.01). Moreover, no apparent side effects were found in both groups. In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.pt_BR
dc.languageen_USpt_BR
dc.publisherElsevierpt_BR
dc.rightsrestrictAccesspt_BR
dc.sourceJournal of Infectionpt_BR
dc.subjectCOVID-19pt_BR
dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)pt_BR
dc.subjectCt valuept_BR
dc.subjectAntiviral therapypt_BR
dc.subjectPneumoniapt_BR
dc.titleArbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19pt_BR
dc.typeArtigopt_BR
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.